Oral miltefosine to treat new world cutaneous leishmaniasis

Lancet Infect Dis. 2007 Jan;7(1):7. doi: 10.1016/S1473-3099(06)70665-X.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Antiprotozoal Agents / administration & dosage
  • Antiprotozoal Agents / adverse effects
  • Antiprotozoal Agents / therapeutic use*
  • Humans
  • Leishmania braziliensis / drug effects
  • Leishmaniasis, Cutaneous / drug therapy*
  • Phosphorylcholine / administration & dosage
  • Phosphorylcholine / adverse effects
  • Phosphorylcholine / analogs & derivatives*
  • Phosphorylcholine / therapeutic use

Substances

  • Antiprotozoal Agents
  • Phosphorylcholine
  • miltefosine